List view / Grid view
In its July meeting, the EMA’s human medicines committee recommended…
In its July meeting, the EMA’s human medicines committee recommended 14 medicines and held a negative opinion for authorising lecanemab to treat Alzheimer’s disease.
New safety data for a Phase IIIb study in treatment-resistant…
New safety data for a Phase IIIb study in treatment-resistant depression (TRD), revealed at ECNC 2023, showed that esketamine NS significantly increased the proportion of patients achieving remission compared to quetiapine XR.
SPRAVATO® achieved significant long-term response rates in treatment-resistant depression, compared…
SPRAVATO® achieved significant long-term response rates in treatment-resistant depression, compared to quetiapine extended release, Janssen’s Phase IIIb study has shown.
